Citi initiated coverage of Kymera Therapeutics (KYMR) with a Buy rating and $52 price target Healthcare policy remains a key biopharma sector ...

Learn more about whether Kymera Therapeutics, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Learn more about whether Kymera Therapeutics, Inc. or Legend Biotech Corporation is a better investment based on AAII's A+ ...

Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025KT-621 Phase 1b trial in atopic dermatitis ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report)’s share price reached a new 52-week low on Friday after the company announced weaker than expected quarterly earnings. The company traded as ...

Kymera Therapeutics Inc (KYMR) reports robust financial health and strategic advancements, setting the stage for significant ...

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the ...

Kymera Therapeutics has a 1 year low of $29.24 and a 1 year high of $53.27. Insider Transactions at Kymera Therapeutics In related news, insider Ellen Chiniara sold 3,129 shares of the stock in a ...

Feb. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for ...